Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cepharanthine - Sairiyo Therapeutics

Drug Profile

Cepharanthine - Sairiyo Therapeutics

Alternative Names: PD-001 - Sairiyo Therapeutics; PD001

Latest Information Update: 21 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sairiyo Therapeutics
  • Class Alkaloids; Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Nonsteroidal anti-inflammatories
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Infections

Most Recent Events

  • 15 May 2024 Sairiyo Therapeutics anticipates Clinical Trial Application approval from Australian Human Research Ethics Committee, regarding initiation of a phase I trial for Cancer and Infections in Australia, in June 2024
  • 15 May 2024 Sairiyo Therapeutics submits Clinical Trial Application for a phase I trial for Cancer and Infections, to Australian Human Research Ethics Committee, for approval
  • 15 May 2024 Sairiyo Therapeutics plans a phase II trial for Cancer and Infections in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top